BibTex format
@article{Rowin:2026:10.1161/CIRCULATIONAHA.125.078597,
author = {Rowin, EJ and Maron, BJ and Siontis, KC and Tower-Rader, AF and Massera, D and Koethe, B and Bilen, O and Phelan, D and Arnold, A and Mohal, JS and Varnava, AM and Schiavo, MA and Ditaranto, R and Biagini, E and Ahamed, H and Hari, A and Johar, S and Lau, B-N and Corrado, D and O'Neill, J and Semsarian, C and Casey, SA and Sharkey, S and Bonaventura, J and Honek, J and Krebsova, A and Adamova, M and McCrystal, D and Scherer, E and Pillai, A and Scalzo, M and Jaiswal, A and Lax, JA and Jurcut, R and Kitaok, H and Smedsrud, MK and Kirshkaln-Leahy, A and Francia, P and Musumeci, B and Hovakimyan, T and Kamel, O and Yacoub, MH and Gunnarsdóttir, OB and Gunnarsson, GT and Adalsteinsdottir, B and Berrios, Barcenas EA and Fifer, MA and Ommen, SR and Sherrid, MV and Maron, MS},
doi = {10.1161/CIRCULATIONAHA.125.078597},
journal = {Circulation},
title = {International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy.},
url = {http://dx.doi.org/10.1161/CIRCULATIONAHA.125.078597},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population. METHODS: Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes. RESULTS: A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (
AU - Rowin,EJ
AU - Maron,BJ
AU - Siontis,KC
AU - Tower-Rader,AF
AU - Massera,D
AU - Koethe,B
AU - Bilen,O
AU - Phelan,D
AU - Arnold,A
AU - Mohal,JS
AU - Varnava,AM
AU - Schiavo,MA
AU - Ditaranto,R
AU - Biagini,E
AU - Ahamed,H
AU - Hari,A
AU - Johar,S
AU - Lau,B-N
AU - Corrado,D
AU - O'Neill,J
AU - Semsarian,C
AU - Casey,SA
AU - Sharkey,S
AU - Bonaventura,J
AU - Honek,J
AU - Krebsova,A
AU - Adamova,M
AU - McCrystal,D
AU - Scherer,E
AU - Pillai,A
AU - Scalzo,M
AU - Jaiswal,A
AU - Lax,JA
AU - Jurcut,R
AU - Kitaok,H
AU - Smedsrud,MK
AU - Kirshkaln-Leahy,A
AU - Francia,P
AU - Musumeci,B
AU - Hovakimyan,T
AU - Kamel,O
AU - Yacoub,MH
AU - Gunnarsdóttir,OB
AU - Gunnarsson,GT
AU - Adalsteinsdottir,B
AU - Berrios,Barcenas EA
AU - Fifer,MA
AU - Ommen,SR
AU - Sherrid,MV
AU - Maron,MS
DO - 10.1161/CIRCULATIONAHA.125.078597
PY - 2026///
TI - International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy.
T2 - Circulation
UR - http://dx.doi.org/10.1161/CIRCULATIONAHA.125.078597
UR - https://www.ncbi.nlm.nih.gov/pubmed/42639666
ER -